Glucagon-like peptide-1 (GLP-1) receptor agonists, initially indicated for type 2 diabetes, obesity care by reducing appetite and improving satiety without nutrient malabsorption. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.